---

title: "Headaches and Migraines: Types, Triggers, and Science-Backed Relief Strategies" slug: "headaches-migraines-types-triggers-relief" category: "brain-health" seo_title: "Headaches & Migraines: Types, Triggers & Relief | VitalPath" meta_description: "From tension headaches to debilitating migraines — learn the types of headaches, common triggers, and evidence-based relief strategies including medications, lifestyle changes, and new CGRP treatments." focus_keywords: "migraine relief, types of headaches, migraine triggers, headache treatment, CGRP migraine, tension headache"

---

Headaches and Migraines: Types, Triggers, and Science-Backed Relief Strategies

By VitalPath Editorial | June 25, 2026 | Brain Health

---

Introduction

Headache disorders are among the most common neurological conditions worldwide. An estimated 40% of the global population experiences tension-type headaches, and approximately 15% suffers from migraines. Migraine alone is the second leading cause of years lived with disability globally and the leading cause among women under 50.

Despite their prevalence and impact, headache disorders remain underdiagnosed and undertreated. Many people suffer for years without effective treatment, either because they have not sought care or because they have been given generic advice that does not address their specific headache type.

The good news: the past decade has seen a revolution in headache medicine, particularly for migraines. New classes of medications — CGRP antagonists — have transformed the lives of many chronic migraine sufferers. And for all headache types, a better understanding of triggers and non-pharmacological strategies has expanded the treatment toolkit.

In this article, we will cover the major headache types, their underlying mechanisms, evidence-based acute and preventive treatments, and lifestyle strategies for reducing headache frequency and severity.

---

Headache Classification: The Major Types

Tension-Type Headache

Prevalence: Most common headache type — lifetime prevalence ~40–78%.

Characteristics:

• Mild-to-moderate, non-pulsating, bilateral pressure or tightness ("band around the head")
• Not aggravated by routine physical activity
• No nausea or vomiting (though either may be present)
• Duration: 30 minutes to 7 days

Mechanism: Not fully understood. Peripheral factors (muscle tension, myofascial trigger points) likely play a role in episodic tension headaches; central sensitization may be involved in chronic forms.

Migraine

Prevalence: ~12% of the population; 3x more common in women.

Characteristics:

• Moderate-to-severe, often unilateral, pulsating/throbbing pain
• Aggravated by routine physical activity
• Associated with nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity)
• Duration: 4–72 hours

Phases of a migraine attack:

1. Prodrome (hours to days before): Fatigue, yawning, neck stiffness, food cravings, mood changes
2. Aura (~25% of migraineurs): Visual disturbances (flashing lights, zigzag lines, blind spots), sensory changes (tingling, numbness), speech difficulties. Develops gradually over 5+ minutes, lasts <60 minutes="minutes">
3. Headache: The pain phase, as described above.
4. Postdrome ("migraine hangover"): Fatigue, cognitive difficulty, mood changes lasting hours to a day.

Mechanism: Migraine is a complex neurovascular disorder involving activation of the trigeminovascular system, release of vasoactive neuropeptides (particularly CGRP — calcitonin gene-related peptide), neurogenic inflammation, and central sensitization. The old theory that migraine is simply a "vascular headache" caused by blood vessel dilation is outdated and incomplete.

Cluster Headache

Prevalence: ~0.1% of the population; 3–4x more common in men.

Characteristics:

• Excruciating, strictly unilateral pain — typically centered around the eye or temple
• Associated with autonomic symptoms on the same side: eye redness/tearing, nasal congestion, eyelid drooping, facial sweating
• Restlessness or agitation during attacks (unlike migraine, where patients prefer to lie still)
• Attacks last 15–180 minutes and occur in clusters — multiple attacks per day for weeks to months, followed by remission periods

Mechanism: Involves activation of the trigeminal-autonomic reflex and the hypothalamus (the brain's master clock, explaining the circadian and seasonal periodicity).

Medication-Overuse Headache

A paradoxical headache disorder caused by frequent use of acute headache medications (≥10–15 days per month, depending on the medication). The headache becomes chronic and refractory until the overused medication is withdrawn. This is one of the most common causes of chronic daily headache.

---

Migraine Triggers: What the Evidence Shows

Triggers are highly individual, and what triggers one person may not affect another. Common triggers include:

| Trigger Category | Examples | |

---

---

---

---

---

--|

---

---

---

-| | Dietary | Alcohol (especially red wine), caffeine (too much or withdrawal), aged cheeses, processed meats (nitrates), artificial sweeteners (aspartame), MSG, skipping meals | | Hormonal | Menstruation (estrogen withdrawal), oral contraceptives, menopause transition | | Sleep | Too little sleep, too much sleep, jet lag, irregular sleep schedule | | Environmental | Bright or flickering lights, strong odors, loud noises, weather changes (barometric pressure) | | Stress | Both during stress and after stress relief ("let-down migraine") | | Physical | Intense exercise, sexual activity, neck tension, jaw clenching |

Important caveat: Many suspected "triggers" may actually be prodromal symptoms. A craving for chocolate before a migraine, for example, may be a prodromal symptom — the migraine is already underway — rather than a trigger.

---

Acute Treatment: Stopping a Headache Once It Starts

Tension-Type Headache

• First-line: Simple analgesics — acetaminophen, NSAIDs (ibuprofen, naproxen)
• Caution: Limit to ≤2–3 days per week to avoid medication-overuse headache

Migraine

The goal of acute migraine treatment is to achieve pain freedom within 2 hours, with sustained relief and minimal side effects.

Non-Specific Medications

| Medication | Notes | |

---

---

---

---

|

---

---

-| | NSAIDs (ibuprofen, naproxen, diclofenac) | Effective for mild-to-moderate attacks; gastric side effects | | Acetaminophen + aspirin + caffeine | Combination products can be effective | | Antiemetics (metoclopramide, prochlorperazine) | Treat nausea and may have analgesic effects |

Migraine-Specific Medications

| Class | Examples | Mechanism | |

---

---

-|

---

---

---

-|

---

---

---

--| | Triptans | Sumatriptan, rizatriptan, eletriptan, zolmitriptan | 5-HT1B/1D receptor agonists; constrict dilated cranial vessels and inhibit CGRP release | | Gepants (CGRP antagonists) | Ubrogepant (Ubrelvy), rimegepant (Nurtec), zavegepant (Zavzpret) | Block CGRP receptor; effective without vasoconstriction | | Ditans | Lasmiditan (Reyvow) | 5-HT1F receptor agonist; effective without vasoconstriction |

Triptans have been the mainstay of acute migraine treatment for decades. They are effective but cause vasoconstriction, making them contraindicated in people with cardiovascular disease, uncontrolled hypertension, or history of stroke.

Gepants and ditans are newer options that do not cause vasoconstriction, making them safer for patients with cardiovascular risk factors.

Cluster Headache

• High-flow oxygen (100% oxygen at 12–15 L/min via non-rebreather mask): Effective within 15 minutes for most patients
• Subcutaneous sumatriptan: Rapid relief; oral triptans are too slow for cluster attacks
• Intranasal triptans or lidocaine: Alternative options

---

Preventive Treatment: Reducing Attack Frequency

When to Consider Prevention

• ≥4 headache days per month with significant disability
• Acute treatments are ineffective, contraindicated, or overused
• Specific headache types (cluster, hemiplegic migraine) where prevention is standard

Oral Preventive Medications for Migraine

| Class | Examples | Notes | |

---

---

-|

---

---

---

-|

---

---

-| | Beta-blockers | Propranolol, metoprolol | Well-established; side effects: fatigue, bradycardia | | Antidepressants | Amitriptyline, venlafaxine | Effective; anticholinergic side effects | | Anticonvulsants | Topiramate, valproate | Topiramate: effective but cognitive side effects; valproate: teratogenic | | Calcium channel blockers | Verapamil | First-line for cluster headache prevention | | ARBs/Candesartan | Candesartan | Modest efficacy; well-tolerated |

CGRP Monoclonal Antibodies: A New Era

The development of monoclonal antibodies targeting CGRP or its receptor represents the first class of medications specifically designed for migraine prevention. They are administered by monthly or quarterly injection:

| Drug | Target | Dosing | |

---

---

|

---

---

--|

---

---

--| | Erenumab (Aimovig) | CGRP receptor | Monthly | | Fremanezumab (Ajovy) | CGRP ligand | Monthly or quarterly | | Galcanezumab (Emgality) | CGRP ligand | Monthly | | Eptinezumab (Vyepti) | CGRP ligand | Quarterly IV |

Efficacy: Approximately 40–50% of patients achieve ≥50% reduction in monthly migraine days. Side effects are generally mild (injection site reactions, constipation with erenumab). These medications have transformed the lives of many patients with chronic migraine who had failed multiple oral preventives.

Botulinum Toxin (Botox)

OnabotulinumtoxinA injections (31 injection sites across the head, neck, and shoulders every 12 weeks) are FDA-approved for chronic migraine (≥15 headache days/month, with ≥8 having migraine features). Efficacy is modest but meaningful for this difficult-to-treat population.

---

Non-Pharmacological Strategies

1. Lifestyle Regularity

Migraine brains dislike change. Maintaining consistent sleep-wake times, meal times, and exercise routines can reduce attack frequency.

2. Stress Management

Stress is the most commonly reported migraine trigger. Evidence-based stress management techniques include:

• Mindfulness-based stress reduction (MBSR)
• Cognitive behavioral therapy (CBT)
• Biofeedback
• Relaxation training

3. Dietary Approaches

• Identify and avoid personal food triggers (keep a headache diary)
• Do not skip meals
• Maintain adequate hydration
• Limit caffeine (both excessive intake and withdrawal can trigger headaches)

4. Supplements with Evidence

| Supplement | Evidence | |

---

---

---

---

|

---

---

---

-| | Magnesium (400–600 mg/day) | Modest evidence for migraine prevention, particularly menstrual migraine and migraine with aura | | Riboflavin (vitamin B2, 400 mg/day) | Modest evidence; well-tolerated | | Coenzyme Q10 (100–300 mg/day) | Modest evidence | | Butterbur (Petasites hybridus) | Evidence of efficacy but concerns about liver toxicity; ensure PA-free preparations | | Feverfew | Mixed evidence |

5. Neuromodulation Devices

Non-invasive devices that modulate neural activity:

• External trigeminal nerve stimulation (eTNS) : Cefaly device
• Single-pulse transcranial magnetic stimulation (sTMS)
• Non-invasive vagus nerve stimulation (nVNS)
• Remote electrical neuromodulation (REN) : Nerivio device

These devices have modest evidence and are options for patients who cannot tolerate or prefer to avoid medications.

---

When to Seek Urgent Evaluation

While most headaches are benign, certain features warrant urgent evaluation:

Red flags ("SNOOP") :

• Systemic symptoms: Fever, weight loss, history of cancer or HIV
• Neurologic symptoms: Confusion, seizures, focal weakness
• Onset: Sudden, severe ("thunderclap" headache reaching peak intensity in <1 minute="minute">
• Older age: New headache after age 50
• Pattern change: Significant change in headache pattern or progressive worsening

These features may indicate secondary causes — subarachnoid hemorrhage, meningitis, temporal arteritis, brain tumor, or other conditions requiring urgent evaluation.

---

Conclusion

Headache disorders — particularly migraines — are among the most common and disabling neurological conditions. They are not "just headaches" — they are legitimate medical conditions with identifiable pathophysiology and effective treatments.

The past decade has seen a remarkable expansion in treatment options, particularly for migraine. CGRP-targeted therapies — both monoclonal antibodies for prevention and gepants for acute treatment — have transformed the landscape, offering effective options with fewer side effects than older medications. Neuromodulation devices and evidence-based non-pharmacological strategies have further expanded the toolkit.

If you suffer from frequent or disabling headaches, seek care from a healthcare provider knowledgeable about headache medicine. Effective treatment exists, and no one should have to suffer in silence.

---

References

1. Goadsby PJ, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiological Reviews. 2017.
2. Dodick DW. Migraine. The Lancet. 2018.
3. Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018.
4. Ashina M, et al. Migraine: integrated approaches to clinical management and emerging treatments. The Lancet. 2021.
5. May A, et al. Cluster headache. Nature Reviews Disease Primers. 2018.

---

🛒 Recommended Products for Brain Health

As an Amazon Associate, we earn from qualifying purchases. This does not affect the price you pay or our editorial integrity.

🔍 Other Excellent Options